Pfizer drive raise prices on 41 of its prescription drugs in January after initially disregard off those plans this summer amid pressure from President Trump.
The treat giant will increase the list price of about 10 percent of its panaceas Jan. 15, the company announced Friday. Most of the increases will be 5 percent, notwithstanding Pfizer will raise three drugs’ list prices by 3 percent and one dope’s by 9 percent.
List prices are the advertised price of a drug, not necessarily the expense insurers pay after discounts, known as rebates.
The news was first come in by the Wall Street Journal.
“We believe the best means to address affordability of physics is to reduce the growing out-of-pocket costs that consumers are facing due to high deductibles and co-insurance, and assure that patients receive the benefit of rebates at the pharmacy counter,” Pfizer’s cordial CEO Ian Read said in a statement.
Trump criticized Pfizer this summer when the Theatre troupe said it would raise prices on about 40 drugs. He tweeted that Pfizer and other drugmakers “should be embarrassed” for increasing drug prices.
Pfizer reversed course and said it commitment hold off on making these increases until the end of the year or until Trump’s blueprint to trim drug prices went into effect. On an earnings call with Stockade drive crazy Street analysts last month, Read said by the end of the year, the gathering’s strategy on price increases would be back to “business as normal.”